Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Crossref DOI link: https://doi.org/10.1186/s13045-016-0243-8
Published Online: 2016-03-10
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Foss, Francine
Horwitz, Steven
Pro, Barbara
Prince, H. Miles
Sokol, Lubomir
Balser, Barbara
Wolfson, Julie
Coiffier, Bertrand